Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data

Anne J Kugler¹
Michael L Thiman²
¹Department of Pharmacy Practice and Administration, Western University of Health Sciences College of Pharmacy, Pomona, CA, USA; ²Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, GA, USA

Abstract: Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from −0.78% to −1.64% over 52–104 weeks, and it consistently outperformed each of these agents. As an add-on therapy, dulaglutide provided additional A1c lowering of −1.4% to −1.44% over monotherapy with glimepiride or glargine at 24 and 28 weeks, respectively. Dulaglutide outperformed exenatide when added to a regimen of metformin with pioglitazone as well as glargine when added to a regimen of metformin with glimepiride. Dulaglutide was shown to be non-inferior to liraglutide when added to metformin. In all AWARD studies other than when compared to liraglutide, dulaglutide at full strength resulted in significantly more patients achieving their A1c goal. Recent class-wide meta-analyses indicate that the incidence of commonly experienced gastrointestinal (GI) side effects is dose dependent, and nausea and vomiting are less common in longer-acting agents such as dulaglutide, but diarrhea may be more common. Pooled data have shown no increased risk of serious side effects such as pancreatitis or neoplasm with the use of dulaglutide. Given the evidence supporting liraglutide’s cardiovascular benefits, the highly anticipated REWIND trial will have a significant impact on the future place in the therapy of dulaglutide.

Keywords: GLP-1 RA, glucagon-like peptide-1 receptor agonist, antidiabetic drugs, diabetes mellitus, injectable, incretin

Introduction
Glucagon-like peptide-1 (GLP-1) agonists act at GLP-1 receptors in pancreatic beta cells to increase intracellular cyclic AMP, which in turn increases glucose-dependent insulin secretion; in addition, they act to decrease glucagon release and slow gastric emptying. Dulaglutide (Trulicity®; Eli Lilly and Company, Indianapolis, IN, USA) is a long-acting GLP-1 agonist that originally received US Food and Drug Administration (FDA) approval in 2014. The longer half-life of dulaglutide compared to earlier GLP-1 agonists is attributable to alterations that decrease DPP-IV hydrolysis as well as linkage to a constant fragment (Fc) that increases protein size and decreases renal clearance.¹

Extensive Phase III study data have been published with regard to dulaglutide, much of which was part of the AWARD studies, which provide evidence for its use in combination with several other antidiabetic agents as well as direct comparisons to several antidiabetic drug classes. Previously published review articles have provided in-depth examinations of the earlier AWARD trials.²⁻⁴ Since the approval of dulaglutide, several
follow-up Phase III and Phase IV data have been published providing additional insights into clinical use of this agent. The purpose of this article is to review emerging clinical data pertaining to the efficacy and safety of dulaglutide in type 2 diabetes mellitus (T2DM).

**Literature search strategy**
A nonsystematic search was conducted on PubMed, Embase, and Cochrane Library using the following search terms: dulaglutide, LY2189265, Trulicity, glucagon-like peptide-1 receptor agonists (RAs), or GLP-1 RA. The limits imposed were English language, human studies, and original research, without any limitation of date range. Articles were filtered manually to remove duplicate studies, conference abstracts, and studies in patients without T2DM. To ensure completeness, bibliographies of relevant review articles and meta-analyses were also reviewed.

**Pharmacokinetics**
The maximum plasma concentration of dulaglutide is achieved at a median of 48 hours following subcutaneous administration, but a period of 2–4 weeks of weekly medication administration is needed to achieve steady state, which is not significantly impacted by the location of injection. Dulaglutide is broken down into its component amino acids by general protein catabolism pathways and is not impacted by the CYP450 isoenzymes or P-glycoprotein. The primary drug interactions of note involve concurrent use of antidiabetic medications such as insulin or sulfonylureas and increased risk of hypoglycemia. Elimination half-life for both the 0.75 and 1.5 mg weekly doses is about 5 days. No dose adjustment is required for age, gender, race, ethnicity, body weight, or renal or hepatic impairment.6

**Mode of administration**
It is recommended to inject dulaglutide subcutaneously in the abdomen, thigh, or upper arm and to rotate the injection site. It is available as a single-dose pen containing 0.5 mL of solution, containing 0.75 or 1.5 mg of active drug and equipped with a locking mechanism to prevent unintentional injection (Figure 1). No additional pen needle prescription is required, as a needle is already a part of the single-use device. No shaking or mixing is required, but the solution should be visually inspected for particulate matter and discoloration prior to administration.6 A medication guide is required to be dispensed with dulaglutide.7

**Review of Phase III trial data**
Within the AWARD study sequence, two trials compared dulaglutide to oral antidiabetic agents, specifically metformin (AWARD-3) and sitagliptin (AWARD-5). AWARD-3 was a 52-week study that randomized patients to dulaglutide (0.75 mg weekly), dulaglutide (1.5 mg weekly), or metformin (twice daily). Enrolled patients included those with baseline A1c values of ≥6.5% and ≤9.5% with only lifestyle management or a single, low-dose oral antidiabetic agent. Previous antidiabetic therapy was discontinued during the study lead-in period. Dulaglutide (1.5 mg) demonstrated a significantly greater A1c reduction from a baseline of 7.6% compared to metformin at 52 weeks, with a significantly greater proportion of patients achieving A1c values of less than both 6.5% and 7% at the study end. No difference in serious adverse events (AEs) was noted, and only constipation was found to occur at a higher rate in the dulaglutide treatment groups compared to metformin. Weight loss was comparable between dulaglutide (1.5 mg) and metformin.8

Details of efficacy parameters in AWARD trials are summarized in Table 1, and select safety end points are detailed in Table 2. AWARD-5 was a 104-week study that randomized patients receiving metformin to either dulaglutide (0.75 mg weekly), dulaglutide (1.5 mg weekly), or sitagliptin (100 mg daily). Patients were eligible for enrollment if they were managed with lifestyle modification only and had baseline A1c values of >8% and ≤9.5% or were managed on two or fewer oral antidiabetic agents with baseline A1c values of ≥7% and ≤9.5%. At study conclusion, both doses of dulaglutide demonstrated significant A1c reduction from baseline
A greater incidence of gastrointestinal (GI) AEs was seen in the dulaglutide 1.5 mg group compared to sitagliptin with significantly greater proportions of patients assigned to either dulaglutide dose achieving A1c values <7% and ≤6.5%. Significantly greater weight loss was seen in the dulaglutide 1.5 mg group compared to sitagliptin. A greater incidence of gastrointestinal (GI) AEs was seen in both dulaglutide groups when compared to sitagliptin. Similar significant improvements in glycemic control were demonstrated in an open-label, nonrandomized study conducted in a Japanese patient population that examined the addition of dulaglutide (0.75 mg weekly) to single-agent oral antidiabetic therapy. For inclusion, patients could be maintained on single-agent therapy with either a sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, or meglitinide. A1c reduction from baseline was significant in all groups and varied from −1.57% to −1.69%.10

Both the AWARD-1 and AWARD-6 studies compared dulaglutide to alternative GLP-1 agonists, exenatide and liraglutide, respectively. AWARD-1 was a 52-week, parallel-arm study that compared multiple doses of dulaglutide to exenatide when added to pioglitazone and metformin background therapy in patients with a mean A1c value of 8.1% at baseline. Patients were randomized to one of four treatment groups including dulaglutide (1.5 or 0.75 mg once weekly), exenatide (10 μg twice daily), or placebo. Both doses of dulaglutide demonstrated significantly greater reductions in A1c at 52 weeks compared to exenatide with a significantly greater proportion of patients achieving A1c values <7% and <6.5% at study conclusion. The lower dulaglutide dose demonstrated significantly fewer total GI AEs compared to exenatide while the higher dulaglutide dose was not significantly different when compared to exenatide.11

AWARD-6 was a 26-week, open-label, non-inferiority study that randomized patients with A1c values of ≥7% and ≤10% while receiving at least 1500 mg of metformin daily to dulaglutide (1.5 mg weekly) or liraglutide (1.8 mg daily). The mean baseline A1c value in both groups was 8.1%. Dulaglutide was found to be non-inferior to liraglutide with regard to A1c reduction from baseline. A greater reduction in body weight was demonstrated in the liraglutide group compared to dulaglutide. No significant differences were noted in treatment-emergent AEs.12 An additional Phase III study in a Japanese patient population lends further data to the comparison of dulaglutide with alternative GLP-1 agonists. In patients randomized to either dulaglutide (0.75 mg weekly) or liraglutide (0.9 mg daily), a significantly greater A1c reduction was seen in the dulaglutide arm.13

### Table 1 Summary of select efficacy parameters in the AWARD study sequence

<table>
<thead>
<tr>
<th>Study design</th>
<th>Study arms</th>
<th>Change in A1c</th>
<th>A1c&lt;7%</th>
</tr>
</thead>
<tbody>
<tr>
<td>A 52-week study of 978 T2DM patients (26-week primary end point; AWARD-1)</td>
<td>DUL 1.5 mg QW; DUL 0.75 mg QW; EXEN 10 μg BID; or placebo (all received MET + sitagliptin)</td>
<td>DUL 1.5 mg QW: −1.51±0.06%;&lt;sup&gt;a&lt;/sup&gt; EXEN 10 μg BID: −0.99±0.06%;&lt;sup&gt;b&lt;/sup&gt; placebo: −0.46±0.08%</td>
<td>DUL 1.5 mg QW: 78%;&lt;sup&gt;c,b&lt;/sup&gt; DUL 0.75 mg QW: 66%;&lt;sup&gt;c&lt;/sup&gt; EXEN 10 μg BID: 52%;&lt;sup&gt;c&lt;/sup&gt; placebo: 43%</td>
</tr>
<tr>
<td>A 78-week study of 810 T2DM patients (52-week primary end point; AWARD-2)&lt;sup&gt;13&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW; DUL 0.75 mg QW; or GLAR daily (all received MET + glimepiride)</td>
<td>DUL 1.5 mg QW: −1.08±0.06%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: −0.67±0.06%;&lt;sup&gt;c&lt;/sup&gt; GLAR daily: −0.63±0.06%</td>
<td>DUL 1.5 mg QW: 53.2%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: 37.1%; GLAR daily: 30.9%</td>
</tr>
<tr>
<td>A 52-week study of 807 T2DM patients (26-week primary end point; AWARD-3)&lt;sup&gt;9&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW; DUL 0.75 mg QW; or MET BID</td>
<td>DUL 1.5 mg QW: −0.78±0.06%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: −0.71±0.06%;&lt;sup&gt;c&lt;/sup&gt; MET BID: −0.56±0.06%</td>
<td>DUL 1.5 mg QW: 62%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: 63%; MET BID: 54%</td>
</tr>
<tr>
<td>A 52-week, open-label study of 884 T2DM patients (26-week primary end point; AWARD-4)&lt;sup&gt;15&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW; DUL 0.75 mg QW; or GLAR QHS (all received insulin lispro)</td>
<td>DUL 1.5 mg QW: −1.64%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: −1.59%;&lt;sup&gt;c&lt;/sup&gt; GLAR QHS: −1.41%</td>
<td>DUL 1.5 mg QW: 68%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: 69%; GLAR QHS: 57%</td>
</tr>
<tr>
<td>A 104-week study of 1098 T2DM patients (52-week primary end point; AWARD-5)&lt;sup&gt;9&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW; DUL 0.75 mg QW; or SIT 100 mg daily</td>
<td>DUL 1.5 mg QW: −1.10±0.06%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: −0.87±0.06%;&lt;sup&gt;c&lt;/sup&gt; SIT 100 mg daily: −0.39±0.06%</td>
<td>DUL 1.5 mg QW: 58%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: 49%; SIT 100 mg daily: 33%</td>
</tr>
<tr>
<td>A 26-week, open-label study of 599 T2DM patients (AWARD-6)&lt;sup&gt;13&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW or LIR 1.8 mg daily (all received MET)</td>
<td>DUL 1.5 mg QW: −1.42±0.05%;&lt;sup&gt;c&lt;/sup&gt; LIR 1.8 mg daily: −1.36±0.05%</td>
<td>DUL 1.5 mg QW: 68%; LIR 1.8 mg daily: 68%</td>
</tr>
<tr>
<td>A 24-week study of 300 T2DM patients (AWARD-8)&lt;sup&gt;19&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW or placebo (all received glimepiride)</td>
<td>DUL 1.5 mg QW: −1.4%;&lt;sup&gt;c&lt;/sup&gt; placebo: −0.1%;&lt;sup&gt;c&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW: 55.3%;&lt;sup&gt;c&lt;/sup&gt; placebo: 18.9%</td>
</tr>
<tr>
<td>A 28-week study of 300 T2DM patients (AWARD-9)&lt;sup&gt;17&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW or placebo (all received GLAR)</td>
<td>DUL 1.5 mg QW: −1.44±0.09%;&lt;sup&gt;c&lt;/sup&gt; placebo: −0.67±0.09%</td>
<td>DUL 1.5 mg QW: 66.7%;&lt;sup&gt;c&lt;/sup&gt; placebo: 33.3%</td>
</tr>
</tbody>
</table>

**Notes:** Significant vs placebo. <sup>a</sup>Significant vs exenatide. <sup>b</sup>Superior vs glargine. <sup>c</sup>Non-inferior vs glargine. <sup>d</sup>Significant vs glargine.<sup>e</sup> Superior vs metformin. <sup>f</sup>Significant vs metformin. <sup>g</sup>Standard error values not reported. <sup>h</sup>Significant vs placebo. <sup>i</sup>Non-inferior vs sitagliptin. <sup>j</sup>Non-inferior vs liraglutide.

**Abbreviations:** AWARD, Assessment of Weekly Administration of LY2189265 (dulaglutide) in Diabetes; BID, twice daily; DUL, dulaglutide; EXEN, exenatide; GLAR, glargine; LIR, liraglutide; MET, metformin; QHS, at bedtime; QW, once weekly; SIT, sitagliptin; T2DM, type 2 diabetes mellitus.
Several AWARD studies have compared dulaglutide to basal insulin, specifically insulin glargine. The AWARD-2 study was a 78-week, open-label, non-inferiority trial that included patients with A1c values of $\geq 7\%$ and $\leq 11\%$ while maintained on one to three oral antidiabetic medications. Patients were randomized to treatment with dulaglutide (0.75 mg weekly), dulaglutide (1.5 mg weekly), or insulin glargine, and all patients received metformin and glimepiride background therapy. Insulin glargine was adjusted using a standardized titration algorithm. A1c reduction with dulaglutide (0.75 mg) was found to be non-inferior to insulin glargine, and all patients received metformin and glimepiride during the study. However, both dulaglutide doses demonstrated a significantly greater proportion of patients achieving an A1c value of $\leq 6.5\%$ at the same time point. Both dulaglutide doses were associated with weight loss, while insulin glargine demonstrated weight gain; this difference was found to be significant. GI AEs were more common in both dulaglutide groups when compared to insulin glargine; however, serious AEs were comparable across treatment groups. AWARD-4 was a 52-week, open-label, non-inferiority trial that enrolled patients with A1c values of $\geq 7\%$ and $\leq 11\%$ while receiving 1–2 doses of insulin per day. Participants were randomized to treatment with dulaglutide (0.75 mg weekly), dulaglutide (1.5 mg weekly), or insulin glargine, with all patients receiving insulin lispro. Patients were permitted to be maintained on metformin during the study; however, no other oral agents were allowed. Dulaglutide (both 0.75 and 1.5 mg) demonstrated significantly greater A1c reduction compared to insulin glargine, although it is noteworthy that significantly greater doses of insulin lispro were utilized in both dulaglutide treatment groups. At study conclusion, dulaglutide (1.5 mg) resulted in a greater proportion of patients achieving an A1c value of $<7.0\%$ compared to insulin glargine, and there were no differences between treatment groups in the proportion of patients achieving an A1c value of $\leq 6.5\%$. Fewer serious AEs occurred in the dulaglutide 1.5 mg group compared to insulin glargine, but GI AEs were more likely in both dulaglutide groups compared to insulin glargine. These results are further supported by an additional Phase III study conducted in a Japanese patient population com-

### Table 2: Summary of select safety parameters in the AWARD study sequence

<table>
<thead>
<tr>
<th>Study</th>
<th>Nausea</th>
<th>Systolic BP change from baseline (mmHg)</th>
<th>HR change from baseline (bpm)</th>
<th>Discontinuation due to AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>AWARD-1&lt;sup&gt;11&lt;/sup&gt; (26-week primary end point)</td>
<td>DUL 1.5 mg QW: 28%;&lt;sup&gt;a&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW: 0.11±0.83;&lt;sup&gt;c&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW: 2.80±0.52;&lt;sup&gt;e&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW: 3%; DUL 0.75 mg QW: 1%; EXEN 10 μg BID: 3%; placebo: 2%</td>
</tr>
<tr>
<td></td>
<td>DUL 0.75 mg QW: 16%;&lt;sup&gt;c&lt;/sup&gt; EXEN 10 μg BID: 26%; placebo: 6%</td>
<td>DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; –0.36±0.82; EXEN 10 μg BID:&lt;sup&gt;c&lt;/sup&gt; 0.06±0.83; placebo: 3.40±1.13</td>
<td>DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; 2.80±0.51;&lt;sup&gt;b&lt;/sup&gt; EXEN 10 μg BID:&lt;sup&gt;c&lt;/sup&gt; 1.18±0.52; placebo: 0.61±0.70</td>
<td>DUL 0.75 mg QW: 2.9%; DUL 0.75 mg QW: 2.6%; GLAR daily: 1.5%</td>
</tr>
<tr>
<td>AWARD-2&lt;sup&gt;14&lt;/sup&gt; (52-week primary end point)</td>
<td>DUL 1.5 mg QW: 14.3%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: 6.6%;&lt;sup&gt;c&lt;/sup&gt; GLAR daily: 1.5%</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; 0.17±0.81; DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; 0.09±0.80; GLAR daily:&lt;sup&gt;c&lt;/sup&gt; 0.51±0.83</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; 1.29±0.50;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; 0.51±0.49; GLAR daily:&lt;sup&gt;c&lt;/sup&gt; –0.52±0.51</td>
<td>DUL 1.5 mg QW: 2.9%; DUL 0.75 mg QW: 2.6%; GLAR daily: 1.5%</td>
</tr>
<tr>
<td>AWARD-3&lt;sup&gt;9&lt;/sup&gt; (26-week primary end point)</td>
<td>DUL 1.5 mg QW: 19%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: 10.7%; MET BID: 14.6%</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; –1.9±0.89; DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; –2.6±0.88; MET BID:&lt;sup&gt;c&lt;/sup&gt; –0.9±0.89</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; 2.4±0.58; DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; 2.1±0.57; MET BID:&lt;sup&gt;c&lt;/sup&gt; 1.6±0.58</td>
<td>DUL 1.5 mg QW: 4.8%; DUL 0.75 mg QW: 2.2%; MET BID: 3.7%</td>
</tr>
<tr>
<td>AWARD-4&lt;sup&gt;13&lt;/sup&gt; (26-week primary end point)</td>
<td>DUL 1.5 mg QW: 26%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: 18%;&lt;sup&gt;c&lt;/sup&gt; GLAR QHS: 3%</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; –0.26; DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; 1.04; GLAR QHS: 1.98&lt;sup&gt;e&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; 2.38;&lt;sup&gt;d&lt;/sup&gt; DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; 2.27;&lt;sup&gt;d&lt;/sup&gt; GLAR QHS: 0.93&lt;sup&gt;e&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW: 11%; DUL 0.75 mg QW: 8%; GLAR QHS: 4%</td>
</tr>
<tr>
<td>AWARD-5&lt;sup&gt;6&lt;/sup&gt; (52-week primary end point)</td>
<td>DUL 1.5 mg QW: 17%;&lt;sup&gt;c&lt;/sup&gt; DUL 0.75 mg QW: 13%; SIT 100 mg daily: 4%</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; –0.8±0.7; DUL 0.75 mg QW:&lt;sup&gt;c&lt;/sup&gt; –0.5±0.7; SIT 100 mg daily:&lt;sup&gt;c&lt;/sup&gt; –0.5±0.7</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; 2.4±0.5; DUL 1.5 mg QW: 2.1±0.5&lt;sup&gt;c&lt;/sup&gt;; SIT 100 mg daily:&lt;sup&gt;c&lt;/sup&gt; –0.3±0.5</td>
<td>DUL 1.5 mg QW: 11%; DUL 0.75 mg QW: 8%; SIT 100 mg daily: 10%</td>
</tr>
<tr>
<td>AWARD-6&lt;sup&gt;12&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW: 20%; LIR 1.8 mg daily: 18%</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; –3.36±0.7; LIR 1.8 mg daily:&lt;sup&gt;c&lt;/sup&gt; –2.82±0.7</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; 2.37±0.4; LIR 1.8 mg daily:&lt;sup&gt;c&lt;/sup&gt; 3.12±0.4</td>
<td>DUL 1.5 mg QW: 6%; LIR 1.8 mg daily: 6%</td>
</tr>
<tr>
<td>AWARD-8&lt;sup&gt;14&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW: 10.5%; placebo: 0%</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; –0.52±0.96; placebo: 0.00±1.54</td>
<td>DUL 1.5 mg QW:&lt;sup&gt;c&lt;/sup&gt; 2.92±0.67; placebo:&lt;sup&gt;c&lt;/sup&gt; 0.30±1.09</td>
<td>DUL 1.5 mg QW: 4.2%; placebo: 0%</td>
</tr>
<tr>
<td>AWARD-9&lt;sup&gt;17&lt;/sup&gt;</td>
<td>DUL 1.5 mg QW: 12.0%; placebo: 1.3%</td>
<td>–</td>
<td>–</td>
<td>DUL 1.5 mg QW: 4%; placebo: 1.3%</td>
</tr>
</tbody>
</table>

**Notes:**<sup>a</sup> Significant vs placebo. Significant vs exenatide. Significant vs glargine. SD/standard error not reported. Significant vs sitagliptin. Not evaluated.

**Abbreviations:** AE, adverse event; AWARD, Assessment of Weekly Administration of LY2189265 (dulaglutide) in Diabetes; BID, twice daily; BP, blood pressure; DUL, dulaglutide; EXEN, exenatide; GLAR, glargine; HR, heart rate; LIR, liraglutide; MET, metformin; QHS, at bedtime; QW, once weekly; SIT, sitagliptin.
paring dulaglutide to insulin glargine in patients maintained on sulfonylurea and/or biguanide. In this patient population, dulaglutide demonstrated a significantly greater A1c reduction compared to insulin glargine.16

A recently published study (AWARD-9) provides additional data for the use of dulaglutide in combination with insulin therapy in patients with T2DM. AWARD-9 was a 28-week, parallel-arm study that randomized patients receiving titrated insulin glargine to either dulaglutide (1.5 mg weekly) or placebo. Patients with A1c values of ≥7% and ≤10.5% who were maintained on a stable dose of insulin glargine were eligible for enrollment. In addition, patients could be maintained on metformin therapy; however, this was not a requirement for inclusion. At baseline, patients’ average age was ~60 years, study groups were 56.7%–58.7% male, average body mass index (BMI) was ~33 kg/m², and an average A1c value was 8.3%–8.4%. A significantly larger reduction in A1c was seen with dulaglutide (−1.44%) compared to placebo (−0.67%), p<0.001. More than 66% of dulaglutide patients achieved an A1c value of <7.0% compared to 33.3% of placebo patients, p<0.001, and 50% of dulaglutide patients reached an A1c value of ≤6.5% compared to 16.7% of patients assigned to placebo, p<0.001. Dulaglutide demonstrated a significant reduction in weight from baseline (~1.91 kg) and resulted in a ~2.41 kg difference compared to placebo, p<0.001. A greater number of treatment-emergent AEs were seen in the dulaglutide treatment group compared to placebo, with a significantly greater incidence of GI AEs and decreased appetite. A significant difference in serious AEs was not demonstrated.17

An additional, more recently published study (AWARD-8) evaluated the impact of adding dulaglutide to background sulfonylurea therapy. This was a 24-week, parallel-arm study that randomized patients maintained on glimepiride to dulaglutide (1.5 mg weekly) or placebo. Patients with A1c values of ≥7.5% and ≤9.5% maintained on a consistent sulfonylurea dose were eligible for enrollment. At baseline, patients’ average age was ~58 years, study groups were 53.3%–56.5% female, average BMI was 30.9–32.4 kg/m², and average A1c value was 8.4%. Dulaglutide demonstrated a significantly greater reduction in A1c compared to placebo resulting in a ~1.3% treatment difference, p<0.001. By the end study, a greater proportion of dulaglutide patients achieved A1c values of <7% and ≤6.5%, 55.3%, and 40%, respectively, compared to placebo patients, 18.9% and 9.4%, respectively, p<0.001 for both comparisons. There was no significant difference in body weight change between groups at study conclusion. Treatment-emergent AEs were comparable between groups; however, a greater incidence in GI AEs was noted in the dulaglutide group compared to placebo. Both total hypoglycemia and symptomatic hypoglycemia were significantly more frequent in those receiving dulaglutide, p<0.05.18

Cardiovascular (CV) impact

A comprehensive meta-analysis of GLP-1 RAs was conducted to investigate the potential impact of these agents on mortality and CV events. A total of 113 trials were included, which used exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, and semaglutide as investigational arms. The risk of all-cause mortality and risk of CV mortality were lower in patients treated with a GLP-1 RA compared to placebo.19 In a meta-analysis of nine randomized, Phase II and III dulaglutide trials, the data of 6010 subjects were pooled, 3885 of whom received dulaglutide. A blinded adjudication committee was used to independently make determinations regarding reported events during the treatment period of each study and up to 30 days following discontinuation of treatment drugs. The primary composite end point included death due to CV cause, nonfatal MI, nonfatal stroke, or hospitalization for unstable angina and resulted in a hazard ratio of 0.57 for patients receiving dulaglutide compared to placebo or active comparator (p=0.046), but no difference when the events were examined separately.20 These data are encouraging, as they support the use of dulaglutide in T2DM without the concern of increased CV risk, at least in the short term. The impact of the long-term use of dulaglutide on the risk of major CV events is currently being examined in the ongoing Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial.21 Final data collection is estimated to be completed by July 2018, and patients will be followed for an average of 6.5 years.

Many GLP-1 RAs agents have been shown to impact patient blood pressure (BP) and heart rate (HR).22 To examine the potential impact of dulaglutide on these vital signs, 755 patients were provided with ambulatory BP monitors and were randomized to dulaglutide at either strength or placebo for 26 weeks. Patients were 56 years old on average, were taking at least one oral medication for the treatment of dia-
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 29-Dec-2018
For personal use only.

betes, and had an average A1c value of 7.9%. Dulaglutide (0.75 mg) was non-inferior to placebo in change to 24-hour BP and HR, while dulaglutide (1.5 mg) showed a statistically significant decrease in systolic BP of 2–3 mmHg and a statistically significant increase in HR of 3–4 bpm.23

Special populations
A post hoc examination of subjects from AWARD 1–6 trials was conducted to explore the efficacy and safety of the use of dulaglutide in Hispanic/Latino patients. Of the studies included, 3136 subjects received dulaglutide and 949 of those subjects self-identified as having Hispanic/Latino ethnicity. Baseline characteristics for subjects of Hispanic/Latino ethnicity were similar to the population at large, except that there were more female patients and the average weight was slightly lower. The percentage of Hispanic/Latino patients who achieved A1c goals, percent reduction in A1c, weight change, and AEs, including hypoglycemia, were similar to the overall population.24

Post hoc analysis of subjects who received dulaglutide in three, non-AWARD, Phase III trials conducted in Japan showed similar efficacy at 26 weeks in 855 subjects, regardless of age or BMI. Elderly patients (>65 years) with a BMI of 25 kg/m², however, were more likely to experience side effects overall than younger patients or elderly patients with a BMI of ≥25 kg/m², with statistically significant differences in the incidences of constipation and decrease in appetite. Subjects were predominantly male (76%), had an average A1c value at baseline of 8.3%, and all were Japanese, making generalizability of these results limited.25 When gender differences were explored in a separate analysis of two of the abovementioned Phase III studies, efficacy of dulaglutide was found to be similar, but greater weight loss (or less weight gain) was seen in female subjects, despite having a lower baseline body weight than male subjects. Females receiving dulaglutide monotherapy lost an average of 1.32 kg, whereas males gained 0.09 kg. When used in combination with a sulfonylurea and/or biguanide, female patients lost an average of 1.13 kg, whereas males lost 0.21 kg. Females experienced more AEs overall than males, and specifically experienced more nausea, constipation, and diarrhea, but there was no difference in incidences of hypoglycemia between genders. Females comprised 23% of the study population (total n=778).26

Additional safety data
Hypoglycemia
In a meta-analysis of 12 Phase II and Phase III, randomized, controlled trials, dulaglutide showed a similar incidence of hypoglycemia when used as monotherapy compared to placebo, metformin, and liraglutide overall (7.8% vs 10.6%; relative risk [RR] 1.07; 95% CI 0.80–1.44). When dulaglutide monotherapy was compared to placebo alone, the RR was 2.58 (95% CI 1.05–6.31), but there was no significant difference detected when compared to metformin or liraglutide individually. A similar pattern was seen when dulaglutide was used as add-on therapy and compared to placebo, sitagliptin, exenatide, liraglutide, and glargine (24.5% vs 24.5%; RR 1.07; 95% CI 0.89–1.30). When add-on dulaglutide was compared to placebo alone, the RR of hypoglycemia was again increased (RR 1.82; 95% CI 1.44–2.31), but as with monotherapy, there was no difference when compared to metformin. A difference was seen compared to sitagliptin 100 mg daily with the 1.5 mg weekly dose of dulaglutide added on (RR 2.14; CI 1.18–3.89), but not the 0.75 mg dose. The risk of hypoglycemia was also greater with dulaglutide add-on when compared to glargine (weighted mean difference [WMD] 0.69; 95% CI 0.56–0.85).27 When data were pooled from three Phase III studies in Japan, older patients, patients with longer-standing diabetes (≥7 years), lower baseline body weight, and subjects with concurrent use of biguanide were all found to be more likely to experience hypoglycemia, but concurrent use of sulfonylurea (SU) was the most significant association with hypoglycemia.28 In a network meta-analysis including 30 unique studies involving once-weekly GLP-1 RAs, nine of which were dulaglutide studies, there were no significant differences found in the frequency of documented or symptomatic hypoglycemia among once-weekly GLP-1 RAs.29

Acute pancreatitis
Data from four Phase II trials and the first five AWARD trials were pooled to assess the risk of acute pancreatitis in patients treated with dulaglutide. Phase II trials ranged from 12 to 26 weeks in length, using doses of 0.1–3.0 mg, and Phase III trials ranged from 52 to 104 weeks, using only doses of 0.75 and 1.5 mg. A total of 6005 subjects were examined, 4006 of whom received dulaglutide. Comparator therapies included placebo, metformin, sitagliptin, exenatide, and insulin glargine. The resulting exposure-adjusted incidence rates of acute pancreatitis were 0.85 patients/1000 patient-years for dulaglutide, 3.52 patients/1000 patient-years for sitagliptin, 4.71 patients/1000 patient-years for exenatide, and 0.89–1.30 for dulaglutide add-on when compared to placebo, sitagliptin 100 mg daily with the 1.5 mg weekly dose of dulaglutide added on (RR 2.14; CI 1.18–3.89), but not the 0.75 mg dose. The risk of hypoglycemia was also greater with dulaglutide add-on when compared to glargine (weighted mean difference [WMD] 0.69; 95% CI 0.56–0.85).27 When data were pooled from three Phase III studies in Japan, older patients, patients with longer-standing diabetes (≥7 years), lower baseline body weight, and subjects with concurrent use of biguanide were all found to be more likely to experience hypoglycemia, but concurrent use of sulfonylurea (SU) was the most significant association with hypoglycemia.28 In a network meta-analysis including 30 unique studies involving once-weekly GLP-1 RAs, nine of which were dulaglutide studies, there were no significant differences found in the frequency of documented or symptomatic hypoglycemia among once-weekly GLP-1 RAs.29

Acute pancreatitis
Data from four Phase II trials and the first five AWARD trials were pooled to assess the risk of acute pancreatitis in patients treated with dulaglutide. Phase II trials ranged from 12 to 26 weeks in length, using doses of 0.1–3.0 mg, and Phase III trials ranged from 52 to 104 weeks, using only doses of 0.75 and 1.5 mg. A total of 6005 subjects were examined, 4006 of whom received dulaglutide. Comparator therapies included placebo, metformin, sitagliptin, exenatide, and insulin glargine. The resulting exposure-adjusted incidence rates of acute pancreatitis were 0.85 patients/1000 patient-years for dulaglutide, 3.52 patients/1000 patient-years for sitagliptin, 4.71 patients/1000 patient-years for exenatide, and 0.89–1.30 for dulaglutide add-on when compared to placebo, sitagliptin 100 mg daily with the 1.5 mg weekly dose of dulaglutide added on (RR 2.14; CI 1.18–3.89), but not the 0.75 mg dose. The risk of hypoglycemia was also greater with dulaglutide add-on when compared to glargine (weighted mean difference [WMD] 0.69; 95% CI 0.56–0.85).27 When data were pooled from three Phase III studies in Japan, older patients, patients with longer-standing diabetes (≥7 years), lower baseline body weight, and subjects with concurrent use of biguanide were all found to be more likely to experience hypoglycemia, but concurrent use of sulfonylurea (SU) was the most significant association with hypoglycemia.28 In a network meta-analysis including 30 unique studies involving once-weekly GLP-1 RAs, nine of which were dulaglutide studies, there were no significant differences found in the frequency of documented or symptomatic hypoglycemia among once-weekly GLP-1 RAs.29
The data from three Phase III trials were pooled to evaluate the risk of acute pancreatitis in the Japanese population when treated with dulaglutide (0.75 mg). Out of 917 patients who received dulaglutide, one occurrence of acute pancreatitis was determined to be drug induced, resulting in an exposure-adjusted incidence rate of 2.651 patients/1000 patient-years. Elevations of amylase (>1× upper limit of normal [ULN] and ≥3× ULN) and lipase (≥3× ULN) were similar in the dulaglutide arms compared to liraglutide, insulin glargine, and placebo arms; however, lipase elevations >1× ULN were significantly higher in the dulaglutide and liraglutide arms than in the insulin glargine and placebo arms. This analysis shares the same limitations as the previous pooled study, but is even smaller and has a maximum study duration of 52 weeks.31

**Neoplasms**

A total of 26 trials involving once-weekly GLP-1 RAs were examined in a meta-analysis to determine whether there was an increased risk of developing tumors of any kind with the use of dulaglutide, exenatide-ER (extended release), or albiglutide. The results indicated that there was not an increased risk of tumor development in any tissues with the use of these three agents, regardless of which agent was selected or the duration of therapy.32

**Comparison to other GLP-1 RAs agents**

**Efficacy**

Although there are no head-to-head trials between dulaglutide and other once-weekly agents, a network meta-analysis including 34 unique studies involving once-weekly GLP-1 RAs was conducted. Out of 34 studies, 10 included dulaglutide; additional agents examined include exenatide weekly, taspoglutide, and albiglutide. Dulaglutide (1.5 mg weekly) was found to have the largest mean A1c reduction compared to placebo (−1.4%). Reduction in fasting plasma glucose (FPG) levels was highest with the use of exenatide weekly (−2.2 mmol/L [CI −2.6 to −1.8 mmol/L]/−39.6 mg/dL [CI −46.8 to −32.4 mg/dL] reduction), followed closely by dulaglutide (1.5 mg), which showed a −2.2 mmol/L (CI −2.6 to −1.7 mmol/L)/−39.6 mg/dL (CI −46.8 to −30.6 mg/dL) reduction. Weight reduction was largest with the use of taspoglutide (20 mg; −1.3 kg; CI −1.9 to −0.7 kg), followed by weekly exenatide and dulaglutide (1.5 mg; −0.8 kg; CI −1.5 to −0.1 kg and −0.8 kg; CI −1.4 to −0.1 kg, respectively).29

**GI side effects**

A systematic meta-analysis examining the incidence of nausea, vomiting, and diarrhea in published Phase III trials involving GLP-1 RAs showed that nausea and diarrhea were both dose-dependent side effects when subjects were treated with GLP-1 RAs, including dulaglutide. The incidence of nausea and vomiting was significantly increased in subjects taking a GLP-1 RA with metformin (p=0.04 and p=0.0009, respectively). Long-acting agents (albiglutide, dulaglutide, exenatide weekly, and liraglutide) generally caused less nausea (p<0.0001) and vomiting (p=0.013), but more diarrhea (p=0.0013) than short-acting agents (exenatide twice daily and lixisenatide) when given at the highest available dose. When compared to liraglutide daily, dulaglutide had similar RR of nausea (p=0.74) and vomiting (p=0.65) and a lower RR of diarrhea (p=0.015). Albiglutide showed a lower RR for all the three, while exenatide weekly showed a lower risk of only nausea when compared to liraglutide.33

The aforementioned network meta-analysis examining once-weekly GLP-1 RAs also calculated odds ratio (OR) for the AE of nausea with use of each agent when compared to placebo. Dulaglutide (1.5 and 0.75 mg) showed moderate ORs (4.35 and 2.44, respectively), with less nausea occurring with use of albiglutide (OR=1.3) and once weekly exenatide (OR=2.38), but more nausea with use of taspoglutide (OR=6.19 for 10 mg strength and OR=8.32 for 20 mg strength).29 In a pooled analysis of three Phase III studies conducted in Japan, female patients, patients with longer-standing diabetes, lower baseline body weight, and those using concurrent SUs were all more likely to experience nausea.28

**Microvascular complications**

A meta-analysis was conducted to investigate the incidence of nephropathy (defined as chronic renal failure, doubling of serum creatinine [SCr], need for continuous renal replacement therapy, or macroalbuminuria) and retinopathy (defined as any AE reported as “retinopathy,” retinal photocoagulation, treatment with intravitreal agents, macular edema, vitreous hemorrhage, retinal detachment, or the onset of diabetes-related blindness) in subjects receiving a GLP-1 RA. Investigators found that, as a class, there was no increased or decreased risk overall for either retinopathy or nephropathy; however, semaglutide was associated with a lower OR for nephropathy, and a higher OR for retinopathy (based on only one study). Liraglutide was associated with a lower risk of retinopathy, while dulaglutide reflected no increased or decreased risk for either microvascular complication.34 A subsequent publication investigating renal outcomes in participants of the LEADER trial found that there were fewer instances of new-onset macroalbuminuria in subjects in the liraglutide arm compared to placebo (hazard ratio 0.74; p=0.0004) after a median follow-up of 3.84 years.
The same study also showed a decreased occurrence of the composite renal outcome (which consisted of new-onset, persistent macroalbuminuria, persistent doubling of the Scr and an estimated glomerular filtration rate \( \geq 45 \text{ mL/min/1.73 m}^2 \), need for continuous renal replacement therapy with no reversible cause of renal disease, or death from renal disease) in the liraglutide arm (hazard ratio 0.78; \( p=0.003 \)).

**Prediction of therapeutic response**

Post hoc analysis of the AWARD-1 and AWARD-5 trial data for patients in the dulaglutide arms showed a strong association between lower fasting blood glucose (FBG) levels at week 2 (<142.2 mg/dL or <7.9 mmol/L) and glycemic response at week 26, which was significant for both strengths of dulaglutide. Glycemic response was defined as either 1) achievement of A1c <7%, 2) A1c reduction of >0.8% if baseline was <8%, 3) A1c reduction of >1.1% if baseline was ≥8% and <9%, or 4) A1c reduction >1.6% if baseline was ≥9%. This may allow for the use of FBG values at week 2 as a predictor of future therapy response, although data did not show an association between high FBG at week 2 and therapy failure.

Data from the first six AWARD trials were pooled to examine baseline characteristics for potential predictors of therapeutic response to dulaglutide treatment at week 26. The primary factor associated with a greater reduction in A1c (−0.594% additional; \( p<0.0001 \)) in the 2806 patients studied was higher baseline A1c. To a much lesser extent, associations were seen between the age group of ≤65 years, fasting serum insulin of ≤55 pmol/L (≤7.92 mIU/L) or eGFR of ≥100 ml/min/1.73 m², and additional A1c lowering of −0.175 (\( p=0.003 \)), −0.197 (\( p<0.0001 \)), and −0.143 (\( p=0.002 \)), respectively. Subjects with lower fasting serum glucose (FSG) exhibited less A1c lowering (+0.0468; \( p<0.0001 \)) than those with higher FSG values at baseline. When data were pooled from the three Phase III trials conducted in Japan, a similar associate was seen between higher A1c and greater response to dulaglutide in A1c lowering; however, subjects with a lower baseline body weight (<70 kg), lower BMI (<25 kg/m²), and higher age (≥65 years) were also likely to experience greater A1c lowering. Patients with a lower baseline A1c were more likely to achieve an A1c goal of <7%. Female subjects, those with lower body weight, higher A1c, and concurrent biguanide therapy tended to lose more weight on dulaglutide. These results suggest that patients in the general population with poorly controlled T2DM are likely to achieve greater A1c lowering than those who are closer to their glycemic goals, and that some Japanese patients may have additional factors that are associated with a stronger response to dulaglutide therapy.

**Patient perspective**

Treatment satisfaction over 52 weeks was examined in subjects from the AWARD-1 and AWARD-3 trials using the Diabetes Treatment Satisfaction Questionnaire, status version (DTSQs) and change version (DTSQc). DTSQs scores were significantly improved at 26 weeks in subjects given dulaglutide (at either strength) when compared to placebo or exenatide, a pattern which persisted at 52 weeks when dulaglutide was compared to exenatide. Subjects on exenatide reported lesser improvement in perceived hyperglycemia compared to subjects receiving dulaglutide, as well as an increase in perceived frequency of hypoglycemia at 26 and 52 weeks. There were no significant differences in DTSQc scores between dulaglutide arms and the metformin arm in AWARD-3, but dulaglutide patients showed a greater improvement in perceived hyperglycemia at 52 weeks.

Additional patient-reported outcome (PRO) questionnaires were used in other AWARD trials. The Ability to Perform Physical Activities of Daily Living (APPADL) and Impact of Weight on Self-Perception (IW-SP) were administered to AWARD-1, AWARD-2, AWARD-3, AWARD-4, and AWARD-6 subjects. Dulaglutide arms showed no significant difference in the APPADL scores when compared to metformin, exenatide, or liraglutide at 26 weeks, which persisted at week 52 for metformin and exenatide comparators. When compared to insulin glargine, results were conflicting. AWARD-2 showed a significantly higher APPADL score for both strengths of dulaglutide compared to glargine at week 52, but at 78 weeks, this difference only persisted for the 1.5 mg dose. In AWARD-4, however, no significant differences in APPADL scores were seen with either strength of dulaglutide when compared to glargine use at 26 or 52 weeks. IW-SP scores were significantly higher in the dulaglutide 1.5 mg group compared to insulin glargine in AWARD-4 (at 26 and 52 weeks) and AWARD-2 (at 78 weeks), but there was no difference when compared to metformin, exenatide, or liraglutide. The Impact of Weight on Quality of Life-Lite (IWQOL-Lite) was administered to AWARD-5 subjects only and showed a significantly higher scoring in the dulaglutide 1.5 mg group compared to sitagliptin at 104 weeks. The Adult Low Blood Sugar Survey (ALBSS) was administered to AWARD-2 and AWARD-4 subjects, but no difference was seen in scores in AWARD-4, while AWARD-2 showed a significantly larger improvement in score in both dulaglutide groups at weeks 52 and 78, including the separate worry and behavior components.

Patients from two other Phase III trials were given the Perceptions about Medications-Diabetes 21 Questionnaire – Japanese
version (PAM-D21-J) and the Injectable Diabetes Medication Questionnaire – Japanese version (IDMQ-J) at week 26 in each study. Patients in these studies were exclusively Japanese and >70% were male, with an average age of 57 years and an A1c value of 8%. Scores for dulaglutide (0.75 mg weekly) in the area of perceived convenience and flexibility were significantly higher than liraglutide (0.9 mg daily), insulin glargine (daily), or placebo; scores for perceived effectiveness and emotional effects were also higher for dulaglutide than glargine or placebo, with no statistically significant difference in perceived physical effects. Higher satisfaction was reported by dulaglutide subjects compared to all other therapies studied. Dulaglutide also scored higher than placebo in ease of use, lifestyle impact, and blood glucose control and higher than glargine in blood glucose control. PRO questionnaires were considered exploratory in this evaluation, as neither were psychometrically validated. It is likely that the better performance overall of dulaglutide on both PROs is driven by its once-weekly administration; however, patients on placebo injections were only required to administer weekly and yet dulaglutide still consistently outperformed placebo with both tools. Of note, PRO studies used prefilled syringes to administer dulaglutide, rather than the commercially available single-use pen, which would likely improve ease of use even further.

Discussion

Phase III studies have demonstrated comparable or superior efficacy of dulaglutide to several therapeutic options in T2DM. As a result, dulaglutide presents a reasonable therapeutic selection for the escalation of therapy in patients maintained on oral therapy as well as those already initiated on basal insulin. In comparison to alternative GLP-1 agonists, dulaglutide has demonstrated superior A1c reduction vs liraglutide and exenatide. Multiple Phase III studies have shown the effectiveness of dulaglutide as second- or third-line therapy in addition to oral hypoglycemic agents, which supports current guideline recommendations for place in therapy of GLP-1 agonists. There are additional Phase III data that support the efficacy of dulaglutide when added to basal insulin, specifically in comparison to placebo; therefore, further study vs an active comparator in the role of escalation of injectable therapy would provide useful insights into appropriate patient selection. Regardless, current evidence does establish dulaglutide as a reasonable therapeutic option in addition to basal insulin.

The 2018 American Diabetes Association (ADA) Standards of Medical Care in diabetes have placed particular focus on the initiation of second-line hypoglycemic agents with proven CV benefits for patients with a history atherosclerotic CV disease. At this time, the only GLP-1 agonist to carry an FDA indication for the reduction in the risk of major CV events is liraglutide. This is based on results of the LEADER trial, which demonstrated a hazard ratio of 0.87; 95% CI 0.78–0.97, p<0.01, for superiority for the primary outcome of first occurrence of death from CV causes, nonfatal MI, or nonfatal stroke. The newly approved GLP-1 agonist, semaglutide, also demonstrated a significant reduction at the primary outcome of the first occurrence of CV death, nonfatal MI, or nonfatal stroke in SUSTAIN-6. This was driven by a reduction in the incidence of nonfatal stroke, which was the only outcome to demonstrate a significant reduction when analyzed separately. It is, however, notable that SUSTAIN-6 was designed as a non-inferiority trial without a prespecified superiority analysis, and the median follow-up was 2.1 years, representing a relatively short study duration. The recently published EXSCEL trial evaluated the CV outcomes of treatment with once-weekly exenatide and found no significant difference in major CV events when compared to placebo. Outside of the class of GLP-1 agonists, separate studies examining the use of empagliflozin and canagliflozin in patients with T2DM and high CV risk showed a reduction in the composite end point of death from CV cause, nonfatal MI, and nonfatal stroke compared to placebo. While some evidence has supported a reduction in overall mortality with dulaglutide, the currently available data have not demonstrated an advantage associated with dulaglutide in terms of CV outcomes. The findings of the ongoing REWIND trial will further define the impact of dulaglutide on CV outcomes, as well as provide insights into whether reduction in CV outcomes may be a class effect of GLP-1 agonists.

Overall, data have demonstrated acceptable tolerability and safety of dulaglutide. Rates of hypoglycemia do not appear to differ significantly from other once-weekly GLP-1 agonists. Pooled data have not demonstrated a significant increase in the risk of pancreatitis compared to placebo; however, the available literature has a number of limitations. Likewise, compiled data to date have not supported an increased risk of neoplasm with the use of dulaglutide. GI AEs present a commonly encountered reason for the discontinuation of GLP-1 agonists. Long-acting GLP-1 agonists, excluding taspoglutide, have demonstrated less nausea and vomiting than short-acting GLP-1 agonists. In comparison to other long-acting agents, dulaglutide has demonstrated a similar risk of nausea compared to liraglutide, but a greater risk of nausea compared to albiglutide and once-weekly exenatide. The available data do not establish an impact of dulaglutide on microvascular complications.
Patient-specific factors that may alter the impact of dulaglutide include female gender (greater weight loss, higher risk of AEs) and elderly patients (>65 years) with normal BMI (higher risk of experiencing side effects). These patterns, however, were seen during ad hoc analyses of studies including only Japanese patients, requiring additional investigation to determine whether they exist in other populations. In the broader population, higher A1c upon initiation and lower FBG values after 2 weeks of therapy may be useful predictors of therapeutic response to dulaglutide.

In terms of the assessment of patient perspective, PRO questionnaires overall indicate that patient perceptions of various quality of life markers with the use of dulaglutide are, at a minimum, equivalent to mainstays of therapy, and in some instances, there is a perceived improvement with dulaglutide use.

Conclusion
Dulaglutide represents a well-tolerated and efficacious option in the treatment of T2DM. Ongoing trial data will better inform the future place in the therapy of dulaglutide considering the recent guideline emphasis on agents with beneficial effects on CV outcomes.

Acknowledgment
The authors would like to acknowledge Palak Desai, Van Kieu, Kelli Shiroma, and Vincent Mach, PharmD candidates 2018, for their role in drafting article summaries.

Disclosure
The authors report no conflicts of interest in this work.

References
47. Trulicity (dulaglutide) injection, solution [instructions for use] Indianapolis, IN: Eli Lilly and Company; 2016.